Home > others & > Orlistat

Orlistat

奥利司他,Ro 18-0647

Orlistat是脂肪酶抑制剂，IC50为122 ng/ml。

目录号
EY0729
EY0729
纯度
99.15%
99.15%
规格
100 mg
500 mg
原价
860
2400
售价
860
2400
库存
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Orlistat is a general lipase inhibitor with IC50 of 122 ng/ml for PL from human duodenal juice.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Knowles, L.M., et al. 2004. J. Biol. Chem. 279: 30540-30545.
    [2] Sternby, B., et al. 2002. Clin Nutr. 21: 395-402.
    [3] Lookene, A., et al. 1994. Eur. J. Biochem. 222: 395-403.

    分子式
    C29H53NO5    		 分子量
    495.73    		 CAS号
    96829-58-2    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    98 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    98 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT01170806 Obesity Drug: Orlistat University of Campinas, Brazil|Germed Pharma 2009-10-01 2011-01-28
    NCT02706067 Obesity Drug: Orlistat Hoffmann-La Roche Phase 4 2002-07-01 2016-04-02
    NCT01414465 Overweight Drug: Orlistat University of Campinas, Brazil|Germed Pharma 2009-10-01 2011-08-10
    NCT02767531 Hyperlipoproteinemia Type I|Hypertriglyceridemia Drug: Orlistat University of Texas Southwestern Medical Center Phase 2 2015-12-01 2016-05-09
    NCT01332448 Obesity Drug: Orlistat 120|Drug: Orlistat 60 GlaxoSmithKline 2010-02-01 2011-04-07
    NCT01003483 Obesity Drug: orlistat Yazd Research & Clinical Center for Infertility|Yazd Medical University Phase 2 2008-11-01 2009-10-27
    NCT01719419 Overweight Drug: Placebo|Drug: Orlistat Pennington Biomedical Research Center 2012-03-01 2015-12-17
    NCT00752726 Obesity|Overweight Drug: Orlistat|Drug: Placebo GlaxoSmithKline Phase 4 2008-09-01 2013-02-28
    NCT00108524 Diabetes Mellitus|Obesity Behavioral: Low carbohydrate ketogenic diet|Drug: Orlistat|Behavioral: Low-fat diet VA Office of Research and Development 2004-07-01 2014-03-26
    NCT01184560 Obesity Drug: Sibutramine|Drug: Orlistat Gachon University Gil Medical Center 2010-02-01 2010-08-18
    NCT00601354 Overweight|Eating Disorders Behavioral: Emotion regulation group therapy|Drug: Orlistat/alli program Stanford University|National Institute of Mental Health (NIMH) 2007-09-01 2013-06-26
    NCT00461799 Crigler-Najjar Syndrome Drug: orlistat University Medical Center Groningen|Erasmus Medical Center|De Najjar Stichting 2003-09-01 2007-04-16
    NCT00001723 Diabetes Mellitus|Hypertension|Metabolic Disease|Obesity|Sleep Apnea Syndrome Drug: Orlistat|Drug: Placebo Jack Yanovski|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|Roche Pharma AG|National Institutes of Health Clinical Center (CC) Phase 2 1998-05-01 2012-11-15
    NCT00991926 Obesity Drug: Orlistat|Other: normo-caloric diet Federico II University Phase 4 2006-12-01 2009-10-13
    NCT01755676 Obesity Drug: Orlistat 60 mg|Other: Placebo EMS Phase 3 2016-09-01 2017-01-25
    NCT01550926 Overweight Drug: 120 mg orlistat|Drug: 60 mg orlistat|Drug: orlistat experimental dose GlaxoSmithKline Phase 1 2009-02-01 2013-01-24
    NCT02529631 Overweight|Obesity Drug: orlistat 60 mg|Device: polyglucosamine Certmedica International GmbH 2009-11-01 2015-08-19
    NCT01035333 Obesity Drug: Orlistat Albany College of Pharmacy and Health Sciences|Albany Medical College Phase 4 2009-11-01 2014-02-25
    NCT01675154 Type 1 Hyperlipoproteinemia Drug: SLx-4090 placebo|Drug: Orlistat Placebo|Drug: Orlistat|Drug: Slx-4090 University of Texas Southwestern Medical Center Phase 2 2015-11-01 2016-05-02
    NCT00152360 Obesity|Heart Diseases Drug: Orlistat University of British Columbia Phase 4 2005-06-01 2013-03-28
    NCT01126970 Obesity Drug: Placebo + Placebo|Drug: 400 mg velneperit (S-2367) + Placebo|Drug: Placebo + 120 mg Orlistat|Drug: 400 mg velneperit (S-2367) + 120 mg Orlistat Shionogi|Shionogi Inc. Phase 2 2010-04-01 2011-09-13
    NCT00292799 Anovulation|Obesity Drug: Orlistat Vs Metformin Sheffield Teaching Hospitals NHS Foundation Trust 2006-02-01 2008-07-15
    NCT01387243 Overweight Drug: Orlistat GlaxoSmithKline 2010-01-01 2012-10-25
    NCT00160407 Fatty Liver|Hepatitis Drug: Orlistat (Xenical)|Behavioral: 1400 kcal diet (30% fat) St. Louis University|Hoffmann-La Roche Phase 4 2003-10-01 2007-11-19
    NCT00207311 Fatty Liver|Hepatitis C Drug: Xenical, Pegasys, Copegus|Behavioral: Xenicare Program Brooke Army Medical Center|Hoffmann-La Roche|The Geneva Foundation Phase 4 2005-08-01 2012-02-13
    NCT00516919 Obesity|Binge Eating Drug: Xenical + behavioral intervention|Behavioral: Behavioral intervention + placebo Yale University|Donaghue Medical Research Foundation Phase 4 2007-08-01 2013-01-07

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：